Lack of ErbB-2 Oncogene Product Overexpression in Soft Tissue Sarcomas

Authors

  • Ofer Merimsky From the Departments of Oncology (O. Merimsky, M. Inbar), Pathology (J. Issakov, I. Schwartz), The National Unit of Orthopedic Oncology (S. Dadia, Y. Kollender, J. Bickels, I. Meller), The Tel-Aviv SouraskyMedical Center, Af. liated with the Sackler School of Medicine, TelAviv University, TelAviv, Israel
  • Josephine Issakov From the Departments of Oncology (O. Merimsky, M. Inbar), Pathology (J. Issakov, I. Schwartz), The National Unit of Orthopedic Oncology (S. Dadia, Y. Kollender, J. Bickels, I. Meller), The Tel-Aviv SouraskyMedical Center, Af. liated with the Sackler School of Medicine, TelAviv University, TelAviv, Israel
  • Ignat Schwartz From the Departments of Oncology (O. Merimsky, M. Inbar), Pathology (J. Issakov, I. Schwartz), The National Unit of Orthopedic Oncology (S. Dadia, Y. Kollender, J. Bickels, I. Meller), The Tel-Aviv SouraskyMedical Center, Af. liated with the Sackler School of Medicine, TelAviv University, TelAviv, Israel
  • Shlomo Dadia From the Departments of Oncology (O. Merimsky, M. Inbar), Pathology (J. Issakov, I. Schwartz), The National Unit of Orthopedic Oncology (S. Dadia, Y. Kollender, J. Bickels, I. Meller), The Tel-Aviv SouraskyMedical Center, Af. liated with the Sackler School of Medicine, TelAviv University, TelAviv, Israel
  • Yehuda Kollender From the Departments of Oncology (O. Merimsky, M. Inbar), Pathology (J. Issakov, I. Schwartz), The National Unit of Orthopedic Oncology (S. Dadia, Y. Kollender, J. Bickels, I. Meller), The Tel-Aviv SouraskyMedical Center, Af. liated with the Sackler School of Medicine, TelAviv University, TelAviv, Israel
  • Jacob Bickels From the Departments of Oncology (O. Merimsky, M. Inbar), Pathology (J. Issakov, I. Schwartz), The National Unit of Orthopedic Oncology (S. Dadia, Y. Kollender, J. Bickels, I. Meller), The Tel-Aviv SouraskyMedical Center, Af. liated with the Sackler School of Medicine, TelAviv University, TelAviv, Israel
  • Moshe Inbar From the Departments of Oncology (O. Merimsky, M. Inbar), Pathology (J. Issakov, I. Schwartz), The National Unit of Orthopedic Oncology (S. Dadia, Y. Kollender, J. Bickels, I. Meller), The Tel-Aviv SouraskyMedical Center, Af. liated with the Sackler School of Medicine, TelAviv University, TelAviv, Israel
  • Isaac Meller From the Departments of Oncology (O. Merimsky, M. Inbar), Pathology (J. Issakov, I. Schwartz), The National Unit of Orthopedic Oncology (S. Dadia, Y. Kollender, J. Bickels, I. Meller), The Tel-Aviv SouraskyMedical Center, Af. liated with the Sackler School of Medicine, TelAviv University, TelAviv, Israel

DOI:

https://doi.org/10.1080/028418602760169424

Abstract

The c- erb B-2 gene and its products (also designated HER -2 and c- neu ) encode for a 185-kd transmembrane glycoprotein with intracellular tyrosine kinase activity. c- erb B-2 belongs to the epidermal growth factor receptor family, of which there are four known members, and has molecular homology to the epidermal growth factor receptor. It seems that this family is critical in control of growth, differentiation, and mobility of many normal and transformed epithelial cell types. We have looked for overexpression of c- erb B-2 gene product in paraffin-embedded material from 230 cases of soft tissue sarcoma, in order to establish a possible new prognostic marker and a potentially new treatment option. In all the cases, irrespective of the sarcoma histological type, the immunostaining for erbB-2 was negative. Applications of erbB-2 for prognostication as well as the option of receptor targeting by trastuzumab monoclonal antibodies were aborted.

Downloads

Download data is not yet available.

Downloads

Published

2002-01-01

How to Cite

Merimsky, O. ., Issakov, J. ., Schwartz, I. ., Dadia, S., Kollender, Y. ., Bickels, J. ., … Meller, I. . (2002). Lack of ErbB-2 Oncogene Product Overexpression in Soft Tissue Sarcomas. Acta Oncologica, 41(4), 366–368. https://doi.org/10.1080/028418602760169424